Accessibility Menu
Alaunos Therapeutics logo

Alaunos Therapeutics(NASDAQ) TCRT

Current Price$2.16
Market Cap$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-99%
1 Year-37%
1 Month-6%
Alaunos Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.032026-07-20
Alaunos Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.59%USD 2.082026-07-13
1 month-5.58%USD 2.152026-06-18
3 month-26.98%USD 2.782026-04-21
Year to date-37.15%USD 3.232025-12-31
1 year-37.35%USD 3.242025-07-18
3 year-97.19%USD 72.122023-07-21
5 year-99.44%USD 360.002021-07-21
Since inception-99.58%USD 487.502005-09-26

Alaunos Therapeutics Financials at a Glance

Market Cap

$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.00K

Net Income (TTM)

-$4.11M

EPS (TTM)

-$2.17

P/E Ratio

-0.94

Dividend

$0.00

Beta (Volatility)

1.46 (Average)

Price

$2.16

Volume

26,500.233

Open

$2.05

Previous Close

$2.03

Daily Range

$2.03 - $2.19

52-Week Range

$1.67 - $4.59

Estimated Earnings Date

Aug 18, 2026

TCRT News

Medical professional holding dollar sign paperweight

Why Alaunos Therapeutics Triumphed On Tuesday

Eric VolkmanSep 20, 2022
Scientist, microscope

Why Alaunos Therapeutics Stock Is Soaring Today

Keith SpeightsSep 16, 2022
Scientists looking at brain scans

Why Alaunos Therapeutics Stock Sank Today

Keith SpeightsSep 12, 2022
Person in a lab looking through a microscope

Why Alaunos Therapeutics Topped the Market on Tuesday

Eric VolkmanSep 6, 2022
growth chart

Why Alaunos Therapeutics Stock Is Up Yet Again Today

George Budwell, PhDSep 1, 2022
man at laptop

Why Alaunos Therapeutics Stock Is Tumbling Today

George Budwell, PhDAug 29, 2022
DNA sequencing genome science lab

Why Alaunos Therapeutics' Shares Jumped 48.9% This Week

James HalleyAug 25, 2022
cancer cells

Why Alaunos Therapeutics Stock Was On Fire Today

George Budwell, PhDAug 25, 2022
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alaunos Therapeutics

Alaunos develops oral medicines for obesity and related metabolic diseases. Its main product aims to help people lose weight without injections. The company focuses on early-stage research for future obesity treatments.

What’s Cooking in the Lab? (Products and Services)

  • ALN1003 (Lead Candidate): Oral drug in preclinical testing for obesity and liver disease; 100% of revenue comes from legacy royalties, not this product.
  • Computational Chemistry Program: Designs new versions of ALN1003 to improve effectiveness and patent protection.
  • Legacy TCR-T Cell Therapy: Discontinued cancer therapy program; no longer in active development.
  • Royalty Revenue: Minor income from a Japanese partner’s cancer drug; represents 100% of current revenue.

Growth Spurts and Strategic Pivots

  • Shifted focus in August 2023 from cancer cell therapies to obesity and metabolic diseases.
  • Discontinued all TCR-T cell therapy programs and related partnerships in 2023.
  • Launched ALN1003 preclinical studies and computational chemistry program in the second half of 2025.
  • Settled outstanding research payments with MD Anderson in 2025, resolving legacy obligations.
  • Entered royalty agreement with Solasia Pharma K.K. for a cancer drug, providing minor ongoing revenue.

Why Alaunos Is a Bit Different

Alaunos targets obesity with a non-hormonal, oral drug approach, unlike most injectable treatments. The company operates with just one employee and relies on outside consultants. Its business model is lean, but faces high execution and funding risks.

Five Things You Need to Know

  • Revenue was $5,000 in 2025, down 50% from 2024, all from royalties.
  • Net loss was $4.18 million in 2025, improved 10.7% from 2024.
  • Research and development spending rose 277% in 2025 as obesity program expanded.
  • Cash and equivalents were $1.39 million at December 31, 2025; runway into Q2 2026.
  • Stockholders’ equity was $2.15 million at year-end 2025, below Nasdaq’s $2.5 million minimum.

Bottom Line

Alaunos has shifted from cancer therapies to early-stage obesity drug research. The company’s future depends on securing funding and advancing its new pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Holger Weis, CPA

Website

www.alaunos.com

Headquarters

Fort Lauderdale, FL 77054, US

TCRT Financials

Key Financial Metrics (TTM)

Gross Margin

-34000.00%

Operating Margin

-138166.63%

Net Income Margin

-136966.67%

Return on Equity

-165.94%

Return on Capital

-196.24%

Return on Assets

-218.22%

Earnings Yield

-1.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.44M

Volume

26.50K

Avg. Volume

15.76K

Financials (TTM)

Gross Profit

-$1.02M

Operating Income

-$4.14M

EBITDA

-$4.09M

Operating Cash Flow

-$3.13M

Capital Expenditure

-$98.00K

Free Cash Flow

-$3.23M

Cash & ST Invst.

$354.00K

Total Debt

$0.00

Alaunos Therapeutics Performance Analysis

Alaunos Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,922,000634.2%
20232023-12-31USD 5,000-99.8%
20242024-12-31USD 10,000100.0%
20252025-12-31USD 5,000-50.0%
Alaunos Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Alaunos Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -26.07-52.7%
20232023-12-31USD -21.97-15.7%
20242024-12-31USD -2.92-86.7%
20252025-12-31USD -2.20-24.8%
Alaunos Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-306.0%
Q32025-09-3012.7%
Q42025-12-3127.3%
Q12026-03-31-47.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$8.00K

+97.7%

Gross Margin

0.00%

N/A

Market Cap

$4.96MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.96M

N/A

Employees

1

N/A

Net Income

-$1.01M

+6.2%

EBITDA

-$998.00K

+7.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$354.00K

+11.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.18%

N/A

Return on Invested Capital

-3.22%

N/A

Free Cash Flow

-$1.03M

-33.5%

Operating Cash Flow

-$1.03M

-33.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RADXRadiopharm Theranostics Limited
$4.28+0.23%
ADXNAddex Therapeutics Ltd
$5.90+3.51%
KTTAPasithea Therapeutics Corp.
$0.46-2.81%
XTLBXTL Biopharmaceuticals Ltd.
$2.90+0.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
MARAMara Holdings
$12.32+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.32+0.06%
TET1 Energy Inc.
$6.14+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.27-0.06%

Questions About TCRT

What is the current price of Alaunos Therapeutics?

Alaunos Therapeutics is trading at $2.09 per share.

What is the 52-week range for Alaunos Therapeutics?

Over the past 52 weeks, Alaunos Therapeutics has traded between $1.67 and $4.59.

How much debt does Alaunos Therapeutics have?

As of the most recent reporting period, Alaunos Therapeutics reported total debt of $0.00.

How much cash does Alaunos Therapeutics have on hand?

Alaunos Therapeutics reported $354.00K in cash and cash equivalents in its most recent financial results.

What is Alaunos Therapeutics’s dividend yield?

Alaunos Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services